Scaffold‐free tissue‐engineered arterial grafts derived from human skeletal myoblasts

Saito, Junichi; Yokoyama, Utako; Nakamura, Takashi; Kanaya, Tomomitsu; Ueno, Takayoshi; Naito, Yuji; Takayama, Toshio; Kaneko, Makoto; Miyagawa, Shigeru; Sawa, Yoshiki; Ishikawa, Yoshihiro

doi:10.1111/aor.13930

Cited by 7 publications

(6 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, in this study, the hardness increase of cell sheets seems to be due to the increase of F-actin expression. On the other hand, collagen secretion is an effective method used to engineer texture which can be achieved with cytokine 34 or mechanical stimulation 35 . In addition, it is possible to further improve texture via long-term culture, manipulation of myoblast orientation, myotube formation 36 , and electrical stimulation.…”

Section: Discussionmentioning

confidence: 99%

Production of scaffold-free cell-based meat using cell sheet technology

et al. 2022

View full text Add to dashboard Cite

In the production of cell-based meat, it is desirable to reduce animal-derived materials as much as possible to meet the challenges of sustainability. Here, we demonstrate the “cell sheet-based meat”: scaffold-free cell-based meat using cell sheet technology and characterize its texture and nutrients. Bovine myoblast cell sheets were prepared using temperature-responsive culture dishes (TRCDs) and 10 stacked cell sheets to fabricate three-dimensional tissue of 1.3–2.7 mm thickness. Hardness was increased by incubation on the TRCD and was further increased by boiling as is characteristic of natural meat. The wet weight percentage of total protein in the cell sheet was about half that of beef. In this method, large-sized items of cell sheet-based meat were also created by simply scaling up the TRCD. This method promises an environment-friendly food product.

show abstract

Section: Discussionmentioning

confidence: 99%

Production of scaffold-free cell-based meat using cell sheet technology

et al. 2022

View full text Add to dashboard Cite

show abstract

“…However, using autologous cells, such as, endothelial and smooth muscle cells, still present several hurdles like limited harvesting potential and the inability to reconstitute neo-tissues due to poor ex vivo differentiation and expansion rates. To overcome these limitations, the use of human skeletal myoblasts has been proposed as an alternative cell source, taking advantage of their high in vitro proliferative capacity ( Saito et al, 2021 ). Another approach could rely on the generation of autologous induced pluripotent stem cells from peripheral blood-derived mononuclear cells and inducing their differentiation towards endothelial and smooth muscle cells to develop TEVGs.…”

Section: Tissue-engineered Vascular Graftsmentioning

confidence: 99%

Clinical implications of inflammation in atheroma formation and novel therapies in cardiovascular diseases

Barungi

Hernández-Camarero²,

Moreno-Terribas³

et al. 2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Cardiovascular diseases (CVD) are the leading causes of death and disability in the world. Among all CVD, the most common is coronary artery disease (CAD). CAD results from the complications promoted by atherosclerosis, which is characterized by the accumulation of atherosclerotic plaques that limit and block the blood flow of the arteries involved in heart oxygenation. Atherosclerotic disease is usually treated by stents implantation and angioplasty, but these surgical interventions also favour thrombosis and restenosis which often lead to device failure. Hence, efficient and long-lasting therapeutic options that are easily accessible to patients are in high demand. Advanced technologies including nanotechnology or vascular tissue engineering may provide promising solutions for CVD. Moreover, advances in the understanding of the biological processes underlying atherosclerosis can lead to a significant improvement in the management of CVD and even to the development of novel efficient drugs. To note, over the last years, the observation that inflammation leads to atherosclerosis has gained interest providing a link between atheroma formation and oncogenesis. Here, we have focused on the description of the available therapy for atherosclerosis, including surgical treatment and experimental treatment, the mechanisms of atheroma formation, and possible novel therapeutic candidates such as the use of anti-inflammatory treatments to reduce CVD.

show abstract

“…On the downside, these grafts are expensive and have a long production time ranging from six to nine months [51]. However, recent studies by Jung et al [50] and Saito et al [53] have shown the feasibility of reducing production time to as low as 35 to 48 days using stem cells or progenitor cells [50,53].…”

Section: Scaffold-free Techniquesmentioning

confidence: 99%

Current Progress in Vascular Engineering and Its Clinical Applications

Jouda

Murillo

Wang

2022

Cells

View full text Add to dashboard Cite

Coronary heart disease (CHD) is caused by narrowing or blockage of coronary arteries due to atherosclerosis. Coronary artery bypass grafting (CABG) is widely used for the treatment of severe CHD cases. Although autologous vessels are a preferred choice, healthy autologous vessels are not always available; hence there is a demand for tissue engineered vascular grafts (TEVGs) to be used as alternatives. However, producing clinical grade implantable TEVGs that could healthily survive in the host with long-term patency is still a great challenge. There are additional difficulties in producing small diameter (<6 mm) vascular conduits. As a result, there have not been TEVGs that are commercially available. Properties of vascular scaffolds such as tensile strength, thrombogenicity and immunogenicity are key factors that determine the biocompatibility of TEVGs. The source of vascular cells employed to produce TEVGs is a limiting factor for large-scale productions. Advanced technologies including the combined use of natural and biodegradable synthetic materials for scaffolds in conjunction with the use of mesenchyme stem cells or induced pluripotent stem cells (iPSCs) provide promising solutions for vascular tissue engineering. The aim of this review is to provide an update on various aspects in this field and the current status of TEVG clinical applications.

show abstract

Scaffold‐free tissue‐engineered arterial grafts derived from human skeletal myoblasts

Cited by 7 publications

References 61 publications

Production of scaffold-free cell-based meat using cell sheet technology

Production of scaffold-free cell-based meat using cell sheet technology

Clinical implications of inflammation in atheroma formation and novel therapies in cardiovascular diseases

Current Progress in Vascular Engineering and Its Clinical Applications

Contact Info

Product

Resources

About